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Abstract
Cognitive deficits in neuropsychiatric disorders, such as Alzheimer’s disease (AD), have been closely related to cholinergic deficits. We have
compared different markers of cholinergic function to assess the best biomarker of cognitive deficits associated to cholinergic hypoactivity. In
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dost-mortem frontal cortex from AD patients, acetylcholine (ACh) levels, cholinacetyltransferase (ChAT) and acetylcholinesterase (AChE)
ctivity were all reduced compared to controls. Both ChAT and AChE activity showed a significant correlation with cognitive deficits. In the
rontal cortex of rats with a selective cholinergic lesion, all cholinergic parameters measured (ACh levels, ChAT and AChE activities, “in
itro” and “in vivo” basal ACh release) were significantly reduced. AChE activity was associated to ChAT activity, and even more, to “in
ivo” and “in vitro” basal ACh release. Quantification of AChE activity is performed by an easy and cheap method and therefore, these results
uggest that determination of AChE activity may be used as an effective first step method to evaluate cholinergic deficits.
2004 Elsevier Ireland Ltd. All rights reserved.
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ognitive deficits in Alzheimer’s disease (AD) have been
idely associated with dysfunction of the cholinergic system
10] consequent upon degeneration of cholinergic cell bodies
n the basal forebrain [12]. Reflecting the loss of cholinergic
nnervation, reductions in acetylcholinesterase (AChE) and
holinacetyltransferase (ChAT) have been reported in AD
rains [13,20,21,37]. It has also been described that in other
ementias, such as parkinsonian dementia, cortical choliner-
ic function is even more severely affected than in AD [2].
Consequent to the cholinergic hypothesis of dementia, an-
mal studies have been used to evaluate the role of cholinergic
eurotransmission in learning and memory and selective le-
ion of cholinergic neurones remains nowadays as a widely
sed method to mimic some aspects of neurodegeneration in
D (see review [28]). In this sense, the most efficient tool to
nduce cholinergic hypoactivity is the immunotoxin 192 IgG-
∗ Corresponding author. Tel.: +34 948425600; fax: +34 948425649.
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saporin [15,23,30]. The verification and extent of the lesion
are commonly assessed by post-mortem measuring of differ-
ent biochemical markers, such as AChE [1,29], ChAT [24,33]
or high-affinity choline uptake (HACU) [26]. All these pa-
rameters could be excellent markers of the extent of lesion or
the amount of surviving cholinergic neurones subsequent to
lesion. However, decreases in cholinergic markers may not
reflect the activity of these remaining neurones due to the
presence of compensatory mechanisms after long-term situ-
ations of cholinergic hypoactivity [17,19]. In addition, total
acetylcholine (ACh) levels are labile in post-mortem tissue,
and ACh released “in vivo” may not be detected in the ab-
sence of AChE inhibitors. Altogether, it is difficult to select
the best cholinergic marker to study a situation of cholinergic
deficit.
In the present work we sought to study the best marker of
cholinergic hypoactivity in relationship to cognitive deficits.
We have measured different cholinergic markers in two sit-
uations of cholinergic hypofunction: (1) in a human study,
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cholinergic function was assessed in post-mortem frontal cor-
tex from AD patients who had been prospectively assessed
with the mini-mental state examination (MMSE) for cogni-
tive impairment and (2) in an animal study, cholinergic pa-
rameters were measured in the frontal cortex of rats subjected
to a selective cholinergic lesion in the nucleus basalis mag-
nocellularis (NBM). Statistical correlations between cholin-
ergic and cognitive deficits have been also carried out.
Cholinergic functions was assessed in post-mortem frontal
cortex (Brodmann area 10, BA10) of 22 patients with clin-
ical diagnosis of dementia and 20 elderly normal controls
matched for age, gender, post-mortem delay and brain pH.
Those patients with dementia were an autopsied subset
of subjects included in a prospective study of behavioural
changes in clinically diagnosed as demented patients [16].
Cognitive status was assessed at 4 monthly intervals using
the mini-mental state examination (MMSE) [8].
Informed consent had been obtained from relatives be-
fore for removal of brain tissue at death. AChE, ChAT and
total ACh levels in human brain tissues were measured as
described by [11]. To partially mitigate the possible effects
of cause of death on neurochemical determinations, brain pH
was measured as an index of acidosis associated with terminal
coma [18]. Post-mortem delay was also considered.
Male Wistar rats were kept at constant room tempera-
t ◦
l
f
w
t
t
f
o
i
a
s
t
i
(
c
a
M
e
r
f
N
S
s
e
d
r
b
b
by Pearson’s or Spearman’s rank correlation coefficients,
according to the normality of variables. Significance was
defined as p≤ 0.05.
The following compounds were used: ketamine (Ke-
tasol, Parke-Davis, USA), xylazine (Rompun, Bayer,
Germany) neostigmine bromide, hemicholinium-3, acetylth-
iocholine iodide (Sigma, UK); [methyl-3H]choline chloride
(86 Ci/mmol, PerkinElmer, USA); [1-14C]acetyl-coenzyme
A (59 mCi/mmol, Amersham Biosciences, UK); 192IgG
Saporin (lot number 21071083, Chemicon International,
Inc., USA). Inorganic salts and other reagents were from
Merck and Sigma.
Demographic details of subjects are shown in Table 1.
In controls, mean value for ACh levels, and AChE and
ChAT activity were 0.36± 0.04 nmol/g tissue, 99.75± 2.80
(absorbance) and 100.01± 9.82 nmol ACh/h g tissue, respec-
tively. In the frontal cortex of AD patients, concentration of
both ACh was significantly reduced (58%) compared to con-
trols. Similarly, AChE and ChAT activities in frontal cor-
tex from AD patients were significantly lower (28.5 and
72.3%, respectively) when compared to control values. ACh
value, in AD patients, was significantly correlated with brain
pH (n= 22; Spearman’s ρ =−0.861*; p= 0.001) and post-
mortem delay (n= 22; Spearman’s ρ =−0.503*; p= 0.033).
There were no significant correlations between brain pH,
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(ure (21± 1 C) and relative humidity (55± 5%) with a 12-h
ight/dark cycle (dark from 8 p.m.) and ad libitum access to
ood and water. A selective cholinergic lesion in the NBM
as produced using the selective toxin 192 IgG-saporin. All
he experiments were carried out in strict compliance with
he recommendations of the EU (DOCE L 358/1 18/2/1986)
or the care and use of laboratory animals. At the beginning
f the study rats were allocated randomly to one of the exper-
mental groups constituted by controls, sham-operated rats
nd rats with 192IgG-saporin lesions.
The production of the lesion was performed as de-
cribed by [14]. Briefly, rats were anaesthetised with a mix-
ure of ketamine (10 mg/kg, i.p.) and xylazine (0.3 mg/kg,
.p.). One microliters of the immunotoxin 192 IgG-Saporin
0.067g/l/hemisphere) was infused bilaterally into the nu-
leus basalis magnocellularis (NBM) of the basal forebrain
t the following coordinates (from bregma): AP −0.9 mm,
L±2.9 mm, DV−6.5 mm. Post-lesion survival times were
stablished at 1 week and 1 month.
AChE activity, ChAT activity, total ACh levels, and ACh
elease both “in vivo” and “in vitro” were measured in the
rontal cortex according to the methods described by [14].
Data were analysed by SPSS for Windows, release 11.0.
ormality was checked by Shapiro–Wilks’s test (p> 0.05).
tudent’s t-test (human studies) or ANOVA test (animal
tudies) were used to study decreases in cholinergic param-
ters. The effects of demographic factors (age, post-mortem
elay and brain pH) on neurochemical variables, intercor-
elation between neurochemical variables or relationships
etween severity of dementia (MMSE score at last interview
efore death) and neurochemical measures were determinedost-mortem delay, length of tissue preservation time and
ChE or ChAT activity Table 1.
In AD patients, cortical AChE and ChAT activities were
ignificantly intercorrelated (n= 21; r= 0.530*; p= 0.019),
hile ACh levels did not correlate with either AChE or ChAT
ctivities.
The mean MMSE score before death was 5± 1 in AD
atients. A statistically significant positive correlation be-
ween last MMSE score and both AChE (n= 21, Spearman’s
= 0.453*; p= 0.045) and ChAT activities (n= 21, Spear-
an’s ρ = 0.473**; p= 0.030) was found. However, ACh lev-
ls failed to show an association with the MMSE score.
In these studies, as there were no statistical differences
nd for simplicity purposes, control non-lesioned and sham
nimal data were combined in one same control group. Simi-
arly, the two lesioned groups (corresponding to 1 week and 1
onth post-lesion time) were combined in a single lesioned
roup. As expected, significant decreases were found in all
holinergic markers measured, as shown in Table 2.
Correlations between all cholinergic parameters are repre-
ented in Fig. 1. In the frontal cortex of animals with a selec-
able 1
emographic features of patients
Control Alzheimer
ge (years) 74.75± 2.67 81.06± 1.60
ender (male/female) 11/9 11/13
ost-mortem delay (h) 39.28± 5.40 51.18± 6.44
H 6.28± 0.16 6.42± 0.54
H, standard chemical symbol, negative log of hydrogen ion concentration.
Control n= 19-20, Alzheimer n= 20-22). Values are mean±S.E.M.
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Table 2
Percentage of remaining activity/levels of different markers after cortical cholinergic dennervation
Post-lesion time AChE activity ChAT activity Total ACh levels “In vivo” basal ACh levels “In vitro” basal ACh levels
1 week 52.89± 4.25 50.96± 4.4 45.91± 4.20 65.57± 3.38 43.33± 1.88
1 month 55.06± 2.73 54.99± 3.93 63.15± 6.21 67.52± 3.51 48.53± 1.91
Total lesion 54.21± 2.93 52.57± 3.26 52.63± 3.88 66.56± 3.45 46.24± 1.80
Data shown as mean±S.E.M. Percentage was calculated in relation to control and sham values. Control values were: AChE (absorbance) = 0.28± 0.032;
ChAT = 139.92± 16.21 nmol ACh/h g tissue; total ACh = 3.82± 0.73 nmol/g tissue; “in vivo” basal ACh levels = 464.15± 24.76 fmol/15l; “in vitro” ACh
levels = 2443.08± 115.49 dpm. The two lesioned groups (corresponding to 1 week and 1 month post-lesion time) were combined in a single lesioned group
(total lesion) for simplicity purposes, as there were no statistical difference between them.
tive cholinergic lesion, AChE activity significantly correlated
with ChAT activity (n= 19; Pearson’s r= 0.556*; p= 0.014),
ACh levels (n= 18; Pearson’s r= 0.505*; p= 0.033), and
ACh release “in vivo” (n= 28; Spearman’s ρ = 0.557*;
p= 0.002).
Disruption of basal forebrain cholinergic pathways and
consequent cortical cholinergic denervation is one of the
hallmarks of AD, together with histopathological changes
such as neurofibrilary tangles and senile plaques [20,21,37].
As expected, profound depletions in all cholinergic markers
F
m
cig. 1. Correlations between different cholinergic parameters measured in the fron
agnocellularis. AChE, acetylcholinesterase; ChAT, coline acetylcholinesterase; A
ontrols; ChAT activity is expressed as nmol ACh/h g tissue; ACh levels are exprestal cortex of rats after a selective cholinergic lesion in the nucleus basalis
Ch, acetylcholine. AChE activity is expressed as % absorbance relative to
sed as nmol/g tissue.
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measured (ACh, ChAT, AChE) were found in frontal cortex
from AD patients in the present study. Data on total levels of
ACh, which are more directly related to neural activity, due
to the degradation of ACh by AChE in post-mortem tissue,
should be taken cautiously. Cholinergic degeneration in AD
has been widely associated with cognitive impairments in the
illness [28]. In our study not only ChAT, but also AChE lev-
els in AD patients showed to be correlated to final MMSE
scores. Decreases in AChE activity have also been described
in several dementing conditions, such as parkinsonian de-
mentia [2] or subcortical ischemic vascular dementia [34].
As the traditional treatment of AD are based on the use of
AChE inhibitors, determination of the remaining AChE ac-
tivity could be a good marker of the expected efficacy of the
treatment to delay the progression of cognitive deficit. Sup-
porting these data, AChE inhibitors such as rivastigmine and
donezepil have been shown to maintain MMSE scores for up
to 52 weeks in placebo-controlled study [27].
With respect to the animal studies, cholinergic neurones
in the NBM give rise to a dense network of cholinergic fibres
innervating the entire cortical mantle [32]. Partial cortical
cholinergic deafferentiation was achieved by intraparenchy-
mal infusion of the selective cholinergic immunotoxin, 192
IgG-Saporin, into the NBM [15,30]. It has been described that
this immunotoxin, at the concentration used in the present
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related to extracellular levels of ACh, reinforcing AChE, as
an excellent candidate to evaluate the effects of a cholinergic
lesion. The AChE activity assay is a fast, cheap and simple
colorimetric method [5,35] compared to the radioenzymatic
assay used to assess ChAT activity [9]. Thus, AChE activity
assay described by [35] might be utilised as a rapid and first
step assay to characterise a situation of cholinergic hypoac-
tivity.
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